A Potent Oncolytic Herpes Simplex Virus for the Therapy of Advanced Prostate Cancer
Annual rept. 1 Jul 2003-30 Jun 2004
BAYLOR COLL OF MEDICINE HOUSTON TX
Pagination or Media Count:
Although conventional radiation therapy and surgery are potentially curative treatments for organ-confined prostate cancer, there are few effective treatments for metastatic disease. We recently created a potent antitumor agent - the fusogenic oncolytic herpes simplex virus HSV. The first task originally planned for the first year of this project was to demonstrate the potency of the fusogenic oncolytic HSV against advanced prostate cancer. The subtasks include a Production of high grade viral stocks b Establishment of metastatic prostate cancer in the animal model c Therapeutic administration of the virus, and evaluation of the results. We have now successfully finished these tasks. We used a mouse model of primary and metastatic human prostate cancer established from PC-3M-Pro4 cells to evaluate three different types of oncolytic HSVs non- fusogenic Baco-1, singly fusogenic Synco-2 and doubly fusogenic Synco-2D. Our results show that the doubly fusogenic Synco-2D has greater oncolytic activity than either Baco-1 or the singly fusogenic Synco-2 virus. Against lung metastases of human prostate cancer xenografts, intravenous administration of Synco-2D had produced a significant reduction of tumor nodules as compared with Synco-2, Baco-1 p0.01 and PBS control. These results demonstrate that the doubly fusogenic Synco-2D indeed is an effective therapeutic agent for human metastatic prostate cancer.
- Medicine and Medical Research